The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC).
J. Medioni
No relevant relationships to disclose
J. Ferrero
No relevant relationships to disclose
G. Deplanque
No relevant relationships to disclose
T. Maurina
No relevant relationships to disclose
J. P. Rodier
No relevant relationships to disclose
E. Raymond
No relevant relationships to disclose
J. Allyon
No relevant relationships to disclose
S. Renaux
Employment or Leadership Position - Hybrigenics
Stock Ownership - Hybrigenics
J. Dufour-Lamartinie
Employment or Leadership Position - Hybrigenics
Stock Ownership - Hybrigenics
S. Oudard
Consultant or Advisory Role - Hybrigenics
Stock Ownership - Hybrigenics